Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial
Baltimore Region: Due to the recent collapse of the Francis Scott Key Bridge, please anticipate delays when travelling to appointments. More information. Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patients with hepatocellular carcinoma, the most common type of liver cancer, according to a clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and its Convergence Institute.
